Video
Author(s):
Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
Pankti Reid, MD, MPH, rheumatologist, assistant professor of medicine, University of Chicago Medicine, discusses remaining challenges regarding the management of immune-related adverse effects (irAEs).
Although the advent of multidisciplinary toxicity teams has facilitated efficient evaluation and management of multi-organ irAEs, challenges remain, Reid says. Moreover, optimization of diagnostic tools and identification of efficacious therapies beyond steroids, is needed.
Systemic steroids, which are currently the standard of care for managing irAEs, are associated with significant toxicities of their own, explains Reid. Additionally, managing irAEs often calls for high-dose steroids given over a long period of time.
As such, developing steroid-sparing regimens is necessary to reduce the potential impact of treatment for irAEs, concludes Reid.
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
2 Commerce Drive
Cranbury, NJ 08512